Patent Application: Multispecific Binding Constructs Against Checkpoint Molecules

This document is a USPTO patent application (US20260085121A1) filed by Compass Therapeutics, LLC, on November 24, 2025. The application describes "Multispecific Binding Constructs Against Checkpoint Molecules and Uses Thereof," focusing on compositions and methods to inhibit tumor evasion by reducing immune checkpoint suppression. Specifically, it details blocking the interaction between PD-1 and its ligand (PD-L1/PD-L2) while promoting cell interaction.

This patent application does not impose immediate regulatory obligations on companies. However, it is relevant for pharmaceutical and biotechnology companies involved in oncology drug development, particularly those working with immune checkpoint inhibitors. Compliance officers in these sectors should be aware of this filing as it pertains to intellectual property in the field of cancer therapeutics and may impact future research and development strategies.